Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 15/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 15/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844641 | 0.81 | CYP1A2 (0.49) | CASP1MTNR1AMTNR1BFLT1KDR | |
| SCHEMBL12304975 | 0.81 | NAMPT (0.49) | CASP1MTNR1AMTNR1B | |
| SCHEMBL2846544 | 0.78 | CYP1A2 (0.48) | CASP1MTNR1AMTNR1BFLT1KDR | |
| SCHEMBL19563522 | 0.77 | CYP3A4 (0.49) | — | |
| SCHEMBL12566028 | 0.77 | LOXL2 (0.47) | CASP1FLT1KDR | |
| SCHEMBL2841416 | 0.76 | HTR1A (0.49) | CASP1MTNR1AMTNR1BFLT1KDR | |
| SCHEMBL12251101 | 0.75 | LOXL2 (0.51) | FLT1KDR | |
| SCHEMBL21879311 | 0.75 | HTT (0.56) | KDR | |
| SCHEMBL7829190 | 0.74 | HDAC1 (0.60) | — | |
| SCHEMBL7834671 | 0.74 | HDAC1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | CASP1 717/4885MTNR1A 2892/4885MTNR1B 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.